Skip to the content
Menu
  • Solutions
    Show sub menu
    • For Companies, Unions, Associations
    • For Advisors & Consultants
    • For Consumers
  • Products
  • Resources
    Show sub menu
    • In The News
    • Insights
    • Media Centre
  • About
    Show sub menu
    • About Us
    • Our Experts
    • Our Team
    • Careers
  • Contact
  • Drugfinder
  • My Request
  • Advisor Login
  • Français
  • Drugfinder
  • My Request
  • Advisor Login
  • Français
Menu
Reformulary Group logo Reformulary Group
  • Solutions
    • For Companies, Unions, Associations
    • For Advisors & Consultants
    • For Consumers
  • Products
  • Resources
    • In The News
    • Insights
    • Media Centre
  • About
    • About Us
    • Our Experts
    • Our Team
    • Careers
  • Contact
Close
Insights

Informulary – Recent changes to the Reformulary® related to oral anti-coagulants (September 2019)

24 September 2019

Related Posts

Insights

Informulary – Recent changes to Diabetes drugs ...

Download Resource

In The News

02 September 2020

Reformulary Group joins BlackNorth Initiative to comb...

Read More

In The News

02 October 2018

Are OHIP+ changes the right prescription? Yes.

Read More

Reformulary Group
  • Resources
    • Insights
    • In The News
    • Media Centre
  • About
    • About Us
    • Our Experts
    • Our Team
    • Careers
  • Contact

    • 55 York Street, Suite 1400
      Toronto, ON
      M5J 1R7

      T. 416-519-9729
      E. hello@reformulary.com

© 2023 Reformulary Group - All Rights Reserved

  • Reformulary Group Privacy Policies
  • DrugFinder Privacy Policies
  • Terms
  • LinkedIn
  • Twitter
  • Facebook
  • YouTube